Kevin Ferro

Mr. Ferro joined Greenhill’s Board of Directors in 2021.

Kevin is the founder of Ferro Holdings LLC, a family-owned holding company. He served as Chief Executive Officer and Chief Investment Officer of Vatera Holdings LLC, an investment advisor with a range of capabilities across traditional and alternative asset classes, from 2006 until its sale in 2018. Prior to Vatera, Kevin founded and served as the Chief Executive Officer and Chief Investment Officer of Ferro Capital LLC, an alternative investments firm with offices in New York and Frankfurt that managed portfolios for clients in the U.S. and Europe. Kevin’s experience also includes posts as Global Head of Alternative Investment Strategies for Commerzbank, where he managed alternative investment portfolios for the bank and its clients, and as Vice President at the D. E. Shaw Group working out of its New York City, London and Tokyo offices.

Kevin has served on numerous boards of public and private companies. Highlights include previously serving as chairman of the board of directors of Pearl Therapeutics, a clinical stage company focused on the development of therapies for chronic respiratory diseases, until its sale to AstraZeneca, and serving as a member of the board of directors of Kos Pharmaceuticals, a specialty pharmaceutical company focused on the treatment of chronic cardiovascular, metabolic and respiratory diseases, until its sale to Abbott Laboratories.

Kevin holds a BA in Government from Harvard University.